$ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ร/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Healthcare
Sector
Biotechnology
Industry
Jan Moller Mikkelsen
CEO
1017
Employees
$248.85
Current Price
$13.71B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 2 | $492,654.00 | 2,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 2 | $492,654.00 | 2,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 2 | $492,654.00 | 2,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 2 | 9 | $777,066.50 | 3,250 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 1,100 | $245.85 | $270,435.00 | View Details |
| Aug 14, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 900 | $246.91 | $222,219.00 | View Details |
| Jun 2, 2026 | SMITH SCOTT THOMAS EVP & Chief Financial Officer | Purchase | 100 | $219.00 | $21,900.00 | View Details |
| May 29, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 100 | $223.50 | $22,350.00 | View Details |
| May 29, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 200 | $222.30 | $44,460.00 | View Details |
| May 29, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 200 | $223.76 | $44,752.00 | View Details |
| May 29, 2026 | SMITH SCOTT THOMAS EVP & Chief Financial Officer | Purchase | 250 | $223.32 | $55,830.00 | View Details |
| May 26, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 200 | $239.37 | $47,873.50 | View Details |
| May 26, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 200 | $236.24 | $47,247.00 | View Details |
1 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: